Imatinib Mesylate for hypereosinophilic syndrome

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 5 Jun 2002: Trial registered, NCT00038675

The trials

NCT00038675: Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate

State
Completed
Phase
No phase
People
125 taking part
Started
Jun 2001
Primary completion
Nov 2013
Arms
Imatinib
Results
Posted on the registry
  1. 5 Jun 2002: Trial registered
  2. 4 Jan 2022: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Kind of treatment: Drug.

Also known as Gleevec, Imatinib accord, Imatinib medac, Imkeldi, Imatinib Mesylate (Gleevec), Imatinib Mesylate 600 MG Oral Tablet, STI571 400 mg, STI571 600 mg.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.